Founded and still located on the EMBL campus in Heidelberg, Cellzome focuses on the identification of a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. In 2012 Cellzome was acquired by GSK.
